Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.58 |
| ▸ | ABL1 | P00519 | 15/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18249851 | 1.00 | LMNA (0.62) | LMNAPOLBHPGDBLMSMN1; SMN2 | |
| SCHEMBL29813235 | 0.89 | LMNA (0.65) | LMNAPOLBHPGDBLMSMN1; SMN2 | |
| SCHEMBL18249873 | 0.89 | LMNA (0.65) | LMNAPOLBHPGDBLMSMN1; SMN2 | |
| SCHEMBL18249837 | 0.88 | ROCK1 (0.66) | LMNAPOLBHPGDBLMSMN1; SMN2 | |
| SCHEMBL29813155 | 0.88 | ROCK1 (0.66) | LMNAPOLBHPGDBLMSMN1; SMN2 | |
| SCHEMBL29813424 | 0.87 | ROCK1 (0.64) | LMNAPOLBHPGDBLMSMN1; SMN2 | |
| SCHEMBL18249841 | 0.87 | ROCK1 (0.64) | LMNAPOLBHPGDBLMSMN1; SMN2 | |
| SCHEMBL29813360 | 0.86 | LMNA (0.67) | LMNAPOLBHPGDBLMSMN1; SMN2 | |
| SCHEMBL18258497 | 0.86 | LMNA (0.67) | LMNAPOLBHPGDBLMSMN1; SMN2 | |
| SCHEMBL18249846 | 0.86 | SMN1; SMN2 (0.62) | LMNAPOLBHPGDBLMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708352-B2 | Anti-cancer compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-07-25 | — | — | US | disclosed |
| US-20220267307-A1 | ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708352-B2 | Anti-cancer compounds | TP53, VHL, BAD | LMNA 2654/4885POLB 714/4885HPGD 1848/4885 |
| US-20220267307-A1 | ANTI-CANCER COMPOUNDS | TP53, VHL, BAD | LMNA 2654/4885POLB 714/4885HPGD 1848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.